NewLink Genetics (NASDAQ:NLNK) received a $26.00 price target from Cantor Fitzgerald in a report released on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 207.51% from the company’s previous close.
A number of other research firms have also recently weighed in on NLNK. Stifel Nicolaus lifted their target price on shares of NewLink Genetics from $14.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, September 11th. ValuEngine cut shares of NewLink Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. Bank of America assumed coverage on shares of NewLink Genetics in a research note on Friday, October 13th. They set a “buy” rating and a $22.00 target price on the stock. BidaskClub upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Friday. Finally, Jefferies Group lowered their target price on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $23.29.
NewLink Genetics (NASDAQ:NLNK) traded down $0.54 on Monday, hitting $8.46. 648,161 shares of the company were exchanged, compared to its average volume of 1,564,400. NewLink Genetics has a 52 week low of $5.90 and a 52 week high of $25.17. The stock has a market cap of $333.69, a PE ratio of -3.47 and a beta of 1.10.
WARNING: “NewLink Genetics (NLNK) Given a $26.00 Price Target by Cantor Fitzgerald Analysts” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2018/01/08/newlink-genetics-nlnk-given-a-26-00-price-target-by-cantor-fitzgerald-analysts.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.